Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $16.30 Consensus Target Price from Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have earned a consensus rating of “Hold” from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $16.30.

A number of equities research analysts recently issued reports on AARD shares. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research report on Monday, July 20th. B. Riley Financial decreased their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. Finally, BTIG Research downgraded Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th.

Institutional Investors Weigh In On Aardvark Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Aardvark Therapeutics during the second quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Aardvark Therapeutics in the 4th quarter worth $47,000. Persistent Asset Partners Ltd bought a new position in shares of Aardvark Therapeutics in the 4th quarter worth $56,000. New York State Common Retirement Fund bought a new position in shares of Aardvark Therapeutics in the 2nd quarter worth $99,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of Aardvark Therapeutics during the 4th quarter valued at $102,000.

Aardvark Therapeutics Price Performance

Shares of NASDAQ:AARD opened at $7.30 on Tuesday. The firm has a fifty day moving average price of $5.28 and a two-hundred day moving average price of $6.78. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94. The company has a market cap of $159.72 million, a price-to-earnings ratio of -2.27 and a beta of 3.81.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. Equities research analysts expect that Aardvark Therapeutics will post -3.48 EPS for the current fiscal year.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.